Daiichi Enters Funded Research Agreement With Cyntellect
Under the terms of the collaboration, Cyntellect will design, configure and run LEAP cell-based assays against a compound collection provided by Daiichi. Specific financial terms were not disclosed.
"We are pleased to establish a formal research relationship with Daiichi, one of Japan's leading pharmaceutical companies," stated Dr. Fred Koller, President and CTO. "Daiichi's commitment to Cyntellect and LEAP represents another important validation of our technology and highlights the unique value proposition presented by combining imaging and cell manipulation in the process of discovering new therapeutics."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.